Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Weight change and long-term cardiovascular outcomes in overweight and obese patients after acute coronary syndromes.

European heart journal open·2026
Same author

Safety of low lipoprotein(a) levels: the FOURIER trial.

European heart journal·2026
Same author

Revue medicale suisse·2026
Same author

[Chronic coronary syndrome : advanced cardiac imaging].

Revue medicale suisse·2026
Same author

[Chagas cardiomyopathy].

Revue medicale suisse·2026
Same author

Erratum to "2025 Focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias" [Atherosclerosis, 409, (October 2025), 120479].

Atherosclerosis·2026

関連する実験動画

Updated: Jun 23, 2026

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

スタチンは免疫調節剤としての作用

François Mach1

  • 1Cardiology Division, Department of Medicine, University Hospital, Geneva Medical School, Foundation for Medical Research, Geneva, Switzerland. francois.mach@medicine.unige.ch

Circulation
|June 3, 2004
PubMed
まとめ
この要約は機械生成です。

スタチンは,メジャー・ヒストコンパティビリティ・コンプレックス・クラスII (MHC-II) 分子の誘導を阻害することによって,免疫反応を抑制する可能性があります. この発見は,スタチンが臓器移植における免疫抑制剤として使用できることを示唆しています.

さらに関連する動画

Purification of Human S100A12 and Its Ion-induced Oligomers for Immune Cell Stimulation
12:55

Purification of Human S100A12 and Its Ion-induced Oligomers for Immune Cell Stimulation

Published on: September 29, 2019

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

関連する実験動画

Last Updated: Jun 23, 2026

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

Purification of Human S100A12 and Its Ion-induced Oligomers for Immune Cell Stimulation
12:55

Purification of Human S100A12 and Its Ion-induced Oligomers for Immune Cell Stimulation

Published on: September 29, 2019

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

科学分野:

  • 免疫学 免疫学とは
  • 薬理学 薬理学とは
  • 細胞生物学 細胞生物学

背景:

  • スタチンは,主にコレステロール合成を低下させることで知られています.
  • コレステロール合成の前駆体であるメバロナートは,細胞機能を調節するイソプレノイド生成にも不可欠です.
  • メジャー・ヒストコンパティビリティ・コンプレックス・クラスII (MHC-II) 分子は,免疫反応と臓器移植の拒絶に不可欠であり,その発現はインターフェロン・ガンマ (IFN-ガンマ) によって誘発され得る.

研究 の 目的:

  • コレステロールの低下を超えてスタチンの潜在的プレオトロプ効果を調査する.
  • スタチンがヒト細胞におけるIFN-ガンマによって誘発されるMHC-II発現の調節に影響を及ぼすかどうかを判断する.

主な方法:

  • 培養されたヒト内皮細胞とモノサイト/マクロファージをスタチンで治療した.
  • IFN-ガンマ誘発MHC-II発現に対するスタチンの効果を分析した.

主要な成果:

  • スタチンはIFN-ガンマによるMHC-II発現誘導を抑制することが観察されました.
  • この抑制は,内皮細胞とモノサイト/マクロファージの両方で発生しました.

結論:

  • スタチンは,MHC-II誘導を阻害することによって,免疫抑制的性質を示す.
  • これらの発見は,臓器移植の臨床試験におけるスタチンの観察された免疫抑制効果の分子説明を提供します.
  • スタチンは,移植環境における免疫抑制剤としての新たな治療法となる可能性があります.